Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039709 · ClinicalTrials.gov registry record · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
A Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Shayan Moosa, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06039709: Recruiting Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Shayan Moosa, MD.
NCT06039709 is a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma that is actively recruiting participants, run by Shayan Moosa, MD. The registered enrollment target is 11 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06039709, a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Shayan Moosa, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. Focused ultrasound (FUS) can be used to non-invasively destroy tumor tissue while preserving normal tissue. When FUS is combined with 5-ALA, this combinatorial approach is called sonodynamic therapy (SDT), and this investigational therapy is being tested for its ability to cause damage to GBM cells. SDT will take place prior to surgery for recurrent GBM.
Primary Outcome
Per NCI Common Terminology Criteria for Adverse Events v5.0
Conditions Studied
Interventions
- COMBINATION_PRODUCT 5-ALA and Low-Intensity Focused Ultrasound (SDT)
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT06039709 shows while recruiting
NCT06039709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which 5-ALA and Low-Intensity Focused Ultrasound (SDT) is the first listed.
NCT06039709 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06039709 about?
NCT06039709 is a clinical study titled "Sonodynamic Therapy in Patients With Recurrent GBM". Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. Fo...
What is the current status of trial NCT06039709?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2024-01-31. Estimated completion is 2026-06.
What conditions does trial NCT06039709 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Recurrent Glioblastoma, GBM.
What interventions are being tested in trial NCT06039709?
The interventions under investigation include: 5-ALA and Low-Intensity Focused Ultrasound (SDT) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06039709?
This trial is sponsored by Shayan Moosa, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06039709 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06039709's enrollment target sits among peer trials
11 80th of 88 higher than 8 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
- NCT06673329 · 11 participants · Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI